Top Canadian Cannabis Player Organigram Goes Global: Inside the Major Expansion Strategy

March 26, 2025

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Positive)

Rhea-AI Summary

Organigram Holdings Inc (NASDAQ: OGI) (TSX: OGI) has announced its rebranding to Organigram Global Inc, marking its evolution from a regional medical cannabis company to a global cannabis leader. The company, which has achieved the #1 market share position in Canada, unveiled a new visual identity including a new logo and website.

The expansion strategy includes a strategic investment in German cannabis leader Sanity Group, which holds 7% market share and distributes to over 2,000 pharmacies. The company is pursuing EU-GMP certification to scale exports and expects higher margins from international sales. Organigram currently exports to Australia, Germany, and the United Kingdom, with plans to increase shipments.

The company maintains two US investments: Open Book Extracts for hemp-derived products and Phylos Bioscience for cannabis genetics. Trading under the symbol ‘OGI’ will continue on both TSX and NASDAQ, with the name change effective March 31, 2025.

Organigram Holdings Inc (NASDAQ: OGI) (TSX: OGI) ha annunciato il suo rebranding in Organigram Global Inc, segnando la sua evoluzione da azienda regionale di cannabis medica a leader globale nel settore della cannabis. L’azienda, che ha raggiunto la posizione di #1 in termini di quota di mercato in Canada, ha svelato una nuova identità visiva che include un nuovo logo e un nuovo sito web.

La strategia di espansione prevede un investimento strategico nel leader tedesco della cannabis, Sanity Group, che detiene una quota di mercato del 7% e distribuisce a oltre 2.000 farmacie. L’azienda sta perseguendo la certificazione EU-GMP per aumentare le esportazioni e si aspetta margini più elevati dalle vendite internazionali. Organigram esporta attualmente in Australia, Germania e Regno Unito, con piani per aumentare le spedizioni.

L’azienda mantiene due investimenti negli Stati Uniti: Open Book Extracts per prodotti derivati dalla canapa e Phylos Bioscience per la genetica della cannabis. Il trading sotto il simbolo ‘OGI’ continuerà sia su TSX che su NASDAQ, con il cambio di nome che entrerà in vigore il 31 marzo 2025.

Organigram Holdings Inc (NASDAQ: OGI) (TSX: OGI) ha anunciado su cambio de marca a Organigram Global Inc, marcando su evolución de una empresa regional de cannabis medicinal a un líder global en el sector del cannabis. La compañía, que ha alcanzado la posición de #1 en cuota de mercado en Canadá, presentó una nueva identidad visual que incluye un nuevo logo y un nuevo sitio web.

La estrategia de expansión incluye una inversión estratégica en el líder alemán de cannabis, Sanity Group, que tiene una cuota de mercado del 7% y distribuye a más de 2,000 farmacias. La empresa está persiguiendo la certificación EU-GMP para escalar las exportaciones y espera márgenes más altos de las ventas internacionales. Organigram actualmente exporta a Australia, Alemania y el Reino Unido, con planes de aumentar los envíos.

La empresa mantiene dos inversiones en EE. UU.: Open Book Extracts para productos derivados del cáñamo y Phylos Bioscience para genética de cannabis. La negociación bajo el símbolo ‘OGI’ continuará tanto en TSX como en NASDAQ, con el cambio de nombre efectivo el 31 de marzo de 2025.

Organigram Holdings Inc (NASDAQ: OGI) (TSX: OGI)는 Organigram Global Inc로 브랜드를 변경한다고 발표하며, 지역 의료 대마초 회사에서 글로벌 대마초 리더로의 발전을 알렸습니다. 캐나다에서 시장 점유율 1위를 달성한 이 회사는 새로운 로고와 웹사이트를 포함한 새로운 시각적 정체성을 공개했습니다.

확장 전략에는 독일 대마초 리더인 Sanity Group에 대한 전략적 투자가 포함되어 있으며, 이 회사는 7%의 시장 점유율을 보유하고 2,000개 이상의 약국에 유통하고 있습니다. 이 회사는 수출 규모를 확장하기 위해 EU-GMP 인증을 추구하고 있으며, 국제 판매에서 더 높은 마진을 기대하고 있습니다. Organigram은 현재 호주, 독일, 영국으로 수출하고 있으며, 선적을 늘릴 계획입니다.

회사는 미국에 두 개의 투자를 유지하고 있습니다: Open Book Extracts는 대마에서 파생된 제품을 위해, Phylos Bioscience는 대마초 유전학을 위해 있습니다. ‘OGI’라는 기호로 거래는 TSX와 NASDAQ 모두에서 계속되며, 이름 변경은 2025년 3월 31일부터 시행됩니다.

Organigram Holdings Inc (NASDAQ: OGI) (TSX: OGI) a annoncé son changement de marque en Organigram Global Inc, marquant son évolution d’une entreprise régionale de cannabis médical à un leader mondial dans le domaine du cannabis. L’entreprise, qui a atteint la position de #1 en part de marché au Canada, a dévoilé une nouvelle identité visuelle comprenant un nouveau logo et un nouveau site web.

La stratégie d’expansion comprend un investissement stratégique dans le leader allemand du cannabis, Sanity Group, qui détient une part de marché de 7% et distribue à plus de 2 000 pharmacies. L’entreprise vise à obtenir la certification EU-GMP pour augmenter les exportations et s’attend à des marges plus élevées sur les ventes internationales. Organigram exporte actuellement vers l’Australie, l’Allemagne et le Royaume-Uni, avec des plans pour augmenter les expéditions.

L’entreprise maintient deux investissements aux États-Unis : Open Book Extracts pour des produits dérivés du chanvre et Phylos Bioscience pour la génétique du cannabis. Le trading sous le symbole ‘OGI’ continuera sur les TSX et NASDAQ, le changement de nom entrant en vigueur le 31 mars 2025.

Organigram Holdings Inc (NASDAQ: OGI) (TSX: OGI) hat sein Rebranding zu Organigram Global Inc angekündigt, was den Übergang von einem regionalen Unternehmen für medizinisches Cannabis zu einem globalen Marktführer im Cannabisbereich markiert. Das Unternehmen, das die Marktanteilsposition #1 in Kanada erreicht hat, stellte eine neue visuelle Identität vor, die ein neues Logo und eine neue Website umfasst.

Die Expansionsstrategie umfasst eine strategische Investition in die deutsche Cannabisführerschaft Sanity Group, die einen Marktanteil von 7% hält und an über 2.000 Apotheken vertreibt. Das Unternehmen strebt die EU-GMP-Zertifizierung an, um Exporte zu skalieren und erwartet höhere Margen aus internationalen Verkäufen. Organigram exportiert derzeit nach Australien, Deutschland und das Vereinigte Königreich und plant, die Lieferungen zu erhöhen.

Das Unternehmen hält zwei Investitionen in den USA: Open Book Extracts für Produkte aus Hanf und Phylos Bioscience für Cannabisgenetik. Der Handel unter dem Symbol ‘OGI’ wird weiterhin sowohl an der TSX als auch an der NASDAQ stattfinden, wobei die Namensänderung am 31. März 2025 in Kraft tritt.

Positive

  • Achieved #1 market share position in Canada
  • Strategic investment in German cannabis leader Sanity Group with 7% market share
  • Pending EU-GMP certification expected to enable higher-margin exports
  • Established export channels to Australia, Germany, and UK
  • Strategic US investments in hemp extracts and proprietary genetics

Negative

Insights

Organigram’s rebranding to Organigram Global represents a significant strategic pivot that extends beyond mere cosmetic changes. This transformation reflects the company’s evolution from a regional Canadian player to a cannabis entity with global ambitions, backed by concrete international investments.

The company’s claim of achieving the #1 market share position in Canada provides a strong foundation for international expansion. Their strategic investment in Germany’s Sanity Group positions them advantageously in Europe’s largest potential cannabis market, with distribution access to over 2,000 pharmacies and approximately 7% market share. The pending EU-GMP certification represents a critical milestone that would unlock scaled European exports with potentially higher margins than domestic sales.

Organigram’s U.S. market strategy includes strategic investments in Open Book Extracts and Phylos Bioscience, providing capabilities in hemp-derived extracts and proprietary genetics—including exclusive access to THCV genetics. These assets could become increasingly valuable as U.S. regulatory frameworks evolve.

The Jupiter investment pool, funded through BAT’s follow-on investment, provides additional capital for international acquisitions without diluting existing shareholders. This creates optionality for Organigram to rapidly capitalize on emerging global opportunities.

This strategic repositioning acknowledges cannabis market maturation in Canada and the need to capture higher-growth international markets for continued expansion. The rebranding aligns corporate identity with this evolved business strategy, signaling a coherent long-term vision beyond domestic operations.

Organigram’s rebrand to Organigram Global formalizes what industry watchers have observed developing over several quarters—a carefully orchestrated international expansion strategy leveraging its domestic success. Reaching the #1 market share position in Canada represents a significant achievement in the world’s most mature federally legal cannabis market, providing credibility as they pursue international opportunities.

The company’s investment in Germany’s Sanity Group is particularly noteworthy as Germany implements its cannabis legalization framework. Sanity’s participation in multiple recreational pilot projects across six German jurisdictions positions Organigram advantageously as this market develops. Germany represents Europe’s largest potential cannabis market by population and economic size.

The pending EU-GMP certification represents a crucial technical milestone that would significantly expand Organigram’s export capabilities. EU-GMP compliance is the strict pharmaceutical manufacturing standard required for medical cannabis imports into European markets, creating meaningful barriers to entry that Organigram appears positioned to overcome.

Their investments in U.S. cannabis technology and genetics companies represent a prudent approach to maintaining optionality in the U.S. market without violating exchange listing requirements. The exclusive access to proprietary THCV genetics through Phylos Bioscience could prove particularly valuable as interest in minor cannabinoids grows.

This strategic repositioning acknowledges the reality that sustainable growth for Canadian LPs must come from international markets as the domestic market matures and faces margin compression.

03/26/2025 – 06:00 AM

TORONTO–(BUSINESS WIRE)–
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is proud to announce its official rebrand to Organigram Global Inc. (“Organigram Global”), a move that demonstrates the Company’s evolution from an East Coast medical cannabis company into a burgeoning global cannabis leader.

Having achieved the number one position in market share in Canada1 and established a growing international footprint, Organigram Global is now focused on accelerating its global expansion and strengthening its presence in key international markets. With strategic international investments and expanding export partnerships, the Company is focused on bringing Canadian-grown, high-quality cannabis to the world.

“As Organigram has grown from its roots in Atlantic Canada to become a global player, our identity needed to evolve alongside our business,” said Beena Goldenberg, CEO of Organigram Global. “We’re not just a Canadian success story—we are a global cannabis innovator, exporting premium products, expanding into international markets, and shaping the future of the cannabis industry. Our new brand identity is a powerful reflection of who we are today.”

A New Look for a New Era

The evolution to Organigram Global includes a bold new logo, a refreshed visual identity, and a new website, reflecting not only the Company’s leadership position in Canada, but its growing international presence and growth ambitions outside of Canada.

Accompanying the visual transformation is the launch of a completely redesigned corporate website. This new platform showcases Organigram Global’s strategic direction, product innovations, and global partnerships, providing an immersive look into the Company’s journey and future ambitions.

Path to Global Expansion

Organigram Global’s international expansion plans include:

  • Strategic investment in German cannabis leader, Sanity Group, which places the Company in a prime position to grow alongside that market. Sanity holds roughly 7% market share, distributes to over 2,000 pharmacies, and is participating in multiple recreational pilot projects with applications pending in six German jurisdictions as well as existing stores in Switzerland.
  • EU-GMP certification is expected to be completed in the upcoming months giving Organigram the ability to scale exports further, which is expected to deliver higher margins, stronger global visibility, and a growing revenue stream.
  • Organigram has been actively finalizing a strategy that positions the Company to participate in the U.S. market in a more meaningful way. In the meantime, Organigram already has two investments in the U.S. creating strategic advantages that expand reach, enhance offerings, and set the Company up for future success. Open Book Extracts provides access to a leader in hemp-derived extracts and formulations and Phylos Bioscience drives innovation in cannabis technology including providing Organigram with exclusive access to proprietary genetics like THCV.
  • Organigram continues to export premium indoor-grown cannabis to Australia, Germany and the United Kingdom and expects to increase shipments in the coming years.

Finally, Organigram continues to identify compelling investment opportunities for Jupiter, the strategic investment pool made possible by BAT’s follow-on investment announced in November 2023. Jupiter aims to actively identify emerging growth opportunities to further expand the Company’s international footprint.

The Future of Organigram Global

“As Organigram Global continues to expand, the new brand identity signals a commitment to international excellence, innovation, and industry leadership. The Company remains dedicated to delivering high-quality, science-backed cannabis products, leveraging its strong foundation in Canada to fuel further global expansion,” said Megan McCrae, Senior Vice President, Global Brands and Corporate Affairs. “Organigram Global is more than a new name—it’s a statement of intent,” added Megan. “We are growing. We are leading. And we are bringing the best of Canadian cannabis to the world.”

Trading on TSX/NASDAQ

As previously announced on March 24, 2025, the name change was approved by shareholders of the Company at the annual and special meeting of shareholders held on the same date. Subject to TSX approval, the Company’s common shares will begin trading on the TSX and NASDAQ under the new name on or about March 31, 2025. The trading symbol will remain unchanged as “OGI”. As part of the name change, the common shares of the Company have been assigned new CUSIP 68617J100 and ISIN CA68617J1003 numbers, and the warrants of the Company have been assigned new CUSIP 68617J118 and ISIN CA68617J1185 numbers. No action is required by existing securityholders of the Company with respect to the name change.

To explore the new Organigram Global identity, visit the newly launched www.organigram.ca.

About Organigram

Organigram Global Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiaries include Organigram Inc., a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada, and Motif Labs Ltd., a licensed cannabis processor.

Organigram is focused on producing high-quality cannabis for adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London will be optimized for labelling, packaging, and national fulfillment. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

Forward-Looking Information

This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information including expectations regarding EU-GMP certification and final approval from the TSX, involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and risks disclosed in the Company’s most recent annual information form, management’s discussion and analysis, management information circular and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

1 Source: HiFyre, February 2025

For Media enquiries:
Megan McCrae, Senior Vice President – Global Brands and Corporate Affairs
megan.mccrae@organigram.ca

For Investor Relations enquiries:
Max Schwartz, Director of Investor Relations
investors@organigram.ca

Source: Organigram Holdings Inc.

FAQ

What markets does Organigram Global (OGI) currently export cannabis to?


Organigram Global exports premium indoor-grown cannabis to Australia, Germany, and the United Kingdom.

What is Organigram’s (OGI) market position in Canada?


Organigram holds the number one position in market share in Canada.

What is Sanity Group’s market share in Germany, where OGI has invested?


Sanity Group holds approximately 7% market share in Germany and distributes to over 2,000 pharmacies.

When will Organigram’s (OGI) name change take effect on stock exchanges?


The name change to Organigram Global will take effect on TSX and NASDAQ around March 31, 2025, maintaining the ‘OGI’ symbol.

What are Organigram’s (OGI) strategic investments in the US market?


OGI has invested in Open Book Extracts for hemp-derived extracts and Phylos Bioscience for proprietary genetics including THCV.

 

Search

RECENT PRESS RELEASES